<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="cause respiratory tract infections in humans. Coronaviruses classify into either" exact="alpha" post="and beta subtypes that infect humans, or into gamma"/>
 <result pre="interferon production culminating in the release of IL-6 and TNF" exact="alpha" post="cytokines [37]. This immune cascade results in extensive tracheobronchial"/>
 <result pre="virus. Liver injury is linked to multiple etiologies such as" exact="alcohol" post="consumption, toxins, bile duct dysfunction, and viral infections. Epidemiologists"/>
 <result pre="development of new drugs and clinical assessment. The antiviral medication" exact="Amantadine" post="is no longer recommended due to the increase in"/>
 <result pre="treatments have demonstrated efficacy for the treatment of COVID-19 including" exact="lopinavir" post="and ritonavir, chloroquine, and hydroxychloroquine that may help to"/>
 <result pre="the treatment of COVID-19 including lopinavir and ritonavir, chloroquine, and" exact="hydroxychloroquine" post="that may help to alleviate symptoms in patients. With"/>
 <result pre="available therapeutic drugs to treat patients with the SARS-CoV-2 infection." exact="Hydroxychloroquine" post="and chloroquine are antiviral drugs that possess similar chemical"/>
 <result pre="drugs to treat patients with the SARS-CoV-2 infection. Hydroxychloroquine and" exact="chloroquine" post="are antiviral drugs that possess similar chemical structures and"/>
 <result pre="action involve targeting lysosome to control graft-versus-host disease in humans." exact="Chloroquine" post="can inhibit the entry of SARS-CoV-2 and prevent virus-host"/>
 <result pre="its binding with SP. This suggests the potential use of" exact="chloroquine" post="in the early stages of infection before the virus"/>
 <result pre="the virus can reduce ACE2 expression and activity [89]. Both" exact="hydroxychloroquine" post="and chloroquine can inhibit certain cellular functions and molecular"/>
 <result pre="can reduce ACE2 expression and activity [89]. Both hydroxychloroquine and" exact="chloroquine" post="can inhibit certain cellular functions and molecular pathways involved"/>
 <result pre="Food and Drug Administration (FDA) has authorized the use of" exact="chloroquine" post="and hydroxychloroquine for emergency treatment of COVID-19 and has"/>
 <result pre="Drug Administration (FDA) has authorized the use of chloroquine and" exact="hydroxychloroquine" post="for emergency treatment of COVID-19 and has the potential"/>
 <result pre="COVID-19 is lopinavir/ritonavir (LPV/r). Lopinavir is a protease inhibitor and" exact="ritonavir" post="is a booster and they are commonly used to"/>
 <result pre="in combination. In vitro studies have demonstrated the ability of" exact="lopinavir" post="in inhibiting SARS-CoV, reducing symptoms such as diarrhea and"/>
 <result pre="the risk of acute respiratory distress syndrome with LPV/r and" exact="ribavirin" post="[88]. The use of LPV/r for treatment of COVID-19"/>
 <result pre="acute kidney injury and secondary infections [90]. A combination of" exact="lopinavir" post="and ritonavir has significantly improved the clinical condition of"/>
 <result pre="injury and secondary infections [90]. A combination of lopinavir and" exact="ritonavir" post="has significantly improved the clinical condition of SARS-CoV patients"/>
 <result pre="effectiveness of oseltamivir against COVD-19 and also in combinations with" exact="chloroquine" post="and favipiravir. However, a study in Wuhan reported no"/>
 <result pre="the entry of the virus. The antimalarial drugs, chloroquine, and" exact="hydroxychloroquine" post="have been shown to inhibit terminal phosphorylation of ACE2"/>
 <result pre="and serve as candidate drugs against the COVID-19 disease [90]." exact="Chloroquine" post="has inhibition activity against SARS-CoV-2Ã‚ at relatively high doses"/>
 <result pre="antiviral drugs being explored including hydroxychloroquine, chloroquine, remdesivir, favipiravir, and" exact="lopinavir" post="and ritonavir may be able to limit the spread"/>
 <result pre="being explored including hydroxychloroquine, chloroquine, remdesivir, favipiravir, and lopinavir and" exact="ritonavir" post="may be able to limit the spread of the"/>
 <result pre="From recent clinical trials, the antiviral drugs remdesivir, favipivir, and" exact="lopinavir" post="and ritonavir can be administered for the treatment of"/>
 <result pre="clinical trials, the antiviral drugs remdesivir, favipivir, and lopinavir and" exact="ritonavir" post="can be administered for the treatment of severe COVID-19"/>
 <result pre="the growth and development by interfering with SP and ACE2." exact="Azithromycin" post="targets SP directly, preventing viral uptake, while hydroxychloroquine interferes"/>
 <result pre="and ACE2. Azithromycin targets SP directly, preventing viral uptake, while" exact="hydroxychloroquine" post="interferes with ACE2 terminal glycosylation, thus weakening SP-ACE2 binding"/>
 <result pre="doses of WJ-MSCs (50*10e6 cells) along with standardized treatment of" exact="hydroxychloroquine" post="and Lopinavir/Ritonavir or Azithromycin and ventilator support. Mortality rate,"/>
 <result pre="cells) along with standardized treatment of hydroxychloroquine and Lopinavir/Ritonavir or" exact="Azithromycin" post="and ventilator support. Mortality rate, sequential organ failure assessment"/>
 <result pre="Chahinian, H., &amp;amp; Yahi, N. (2020). Synergistic antiviral effect of" exact="hydroxychloroquine" post="and azithromycin in combination against SARS-CoV-2: what molecular dynamics"/>
 <result pre="&amp;amp; Yahi, N. (2020). Synergistic antiviral effect of hydroxychloroquine and" exact="azithromycin" post="in combination against SARS-CoV-2: what molecular dynamics studies of"/>
</results>
